留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

全面评估,合理决策:基于胰高血糖素样肽1受体激动剂用药风险的最新发现

何丽云 张化冰 李玉秀

何丽云, 张化冰, 李玉秀. 全面评估,合理决策:基于胰高血糖素样肽1受体激动剂用药风险的最新发现[J]. 协和医学杂志, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
引用本文: 何丽云, 张化冰, 李玉秀. 全面评估,合理决策:基于胰高血糖素样肽1受体激动剂用药风险的最新发现[J]. 协和医学杂志, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391
Citation: HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. doi: 10.12290/xhyxzz.2022-0391

全面评估,合理决策:基于胰高血糖素样肽1受体激动剂用药风险的最新发现

doi: 10.12290/xhyxzz.2022-0391
基金项目: 

北京市自然科学基金 M22014

中国医学科学院医学与健康科技创新工程项目 2021-1-I2M-002

详细信息
    通讯作者:

    张化冰, E-mail: huabingzhangchn@163.com

  • 中图分类号: R589;R452

Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists

Funds: 

Beijing Natural Science Foundation M22014

CAMS Innovation Fund for Medical Sciences 2021-1-I2M-002

More Information
  • 摘要: 胰高血糖素样肽1受体激动剂(glucagon-like peptide-1 receptor agonists, GLP-1RAs)作为一种新型降糖药物,被广泛应用于2型糖尿病的治疗。GLP-1RAs能够有效降低血糖且低血糖风险小,此外,GLP-1RAs减重效果显著,兼具一定的心血管及肾脏保护作用; 轻中度胃肠道症状是GLP-1RAs最常见的不良反应,一般随时间延长可逐渐减轻。最新研究显示,GLP-1RAs的使用与胆囊或胆道疾病发生风险相关,尤其在高剂量、长时间使用以及用于减重治疗时,风险显著增加,但胆囊或胆道疾病的绝对风险不高。临床医生需全面权衡GLP-1RAs使用的获益与风险,并与患者共同作出合理决策。
    作者贡献:何丽云、张化冰负责查阅文献、撰写论文; 张化冰、李玉秀负责论文构思及终稿审核、修订。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence[J]. Nat Rev Nephrol, 2021, 17: 227-244. doi:  10.1038/s41581-020-00367-2
    [2] Kalyani RR. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes[J]. N Engl J Med, 2021, 384: 1248-1260. doi:  10.1056/NEJMcp2000280
    [3] Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes[J]. Lancet Diabetes Endocrinol, 2021, 9: 525-544. doi:  10.1016/S2213-8587(21)00113-3
    [4] Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care[J]. Lancet Diabetes Endocrinol, 2021, 9: 46-52. doi:  10.1016/S2213-8587(20)30343-0
    [5] Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison[J]. J Am Coll Cardiol, 2022, 79: 1849-1857.
    [6] Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J]. Mol Metab, 2021, 46: 101102. doi:  10.1016/j.molmet.2020.101102
    [7] Ceriello A, Prattichizzo F, Phillip M, et al. Glycaemic management in diabetes: old and new approaches[J]. Lancet Diabetes Endocrinol, 2022, 10: 75-84. doi:  10.1016/S2213-8587(21)00245-X
    [8] Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials[J]. BMJ, 2021, 372: m4573.
    [9] Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications[J]. Lancet, 2021, 398: 262-276. doi:  10.1016/S0140-6736(21)00536-5
    [10] Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol, 2021, 9: 653-662. doi:  10.1016/S2213-8587(21)00203-5
    [11] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13: 315-409. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK202108007.htm
    [12] Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline[J]. BMJ, 2021, 373: n1091.
    [13] Marx N, Grant PJ, Cosentino F. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk[J]. Eur Heart J, 2020, 41: 329-330. doi:  10.1093/eurheartj/ehz853
    [14] He L, Yang N, Xu L, et al. Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis[J]. Diabetes Ther, 2020, 11: 2121-2143. doi:  10.1007/s13300-020-00882-2
    [15] Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes[J]. Diabetes Care, 2021, 44: 1236-1241. doi:  10.2337/dc20-3007
    [16] Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial[J]. JAMA, 2015, 314: 687-699. doi:  10.1001/jama.2015.9676
    [17] Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management[J]. N Engl J Med, 2015, 373: 11-22. doi:  10.1056/NEJMoa1411892
    [18] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity[J]. N Engl J Med, 2021, 384: 989-1002. doi:  10.1056/NEJMoa2032183
    [19] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: the STEP 4 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1414-1425. doi:  10.1001/jama.2021.3224
    [20] Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: the STEP 3 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1403-1413. doi:  10.1001/jama.2021.1831
    [21] Christensen RM, Juhl CR, Torekov SS. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists[J]. Drug Saf, 2019, 42: 957-971. doi:  10.1007/s40264-019-00812-7
    [22] US Food, Drugs Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014[EB/OL]. (2021-06-04)[2022-07-01]. https://www.fda.gov/news-events/press-announcements/fda-appro- ves-new-drug-treatment-chronic-weight-management-first-2014.
    [23] Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials[J]. Diabetes Obes Metab, 2017, 19: 336-347. doi:  10.1111/dom.12824
    [24] Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study[J]. JAMA Intern Med, 2013, 173: 534-539. doi:  10.1001/jamainternmed.2013.2720
    [25] Douros A, Filion KB, Yin H, et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy[J]. Diabetes Care, 2018, 41: 2330-2338. doi:  10.2337/dc17-2280
    [26] Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106: 912-921. doi:  10.1210/clinem/dgaa891
    [27] Pizzimenti V, Giandalia A, Cucinotta D, et al., Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database[J]. J Clin Pharm Ther, 2016, 41: 116-118. doi:  10.1111/jcpt.12373
    [28] Faillie JL, Yu OH, Yin H, et al. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus[J]. JAMA Intern Med, 2016, 176: 1474-1481. doi:  10.1001/jamainternmed.2016.1531
    [29] Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined[J]. N Engl J Med, 2021, 384: 1719-1730. doi:  10.1056/NEJMoa2028198
    [30] le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial[J]. Lancet, 2017, 389: 1399-1409. doi:  10.1016/S0140-6736(17)30069-7
    [31] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375: 1834-1844. doi:  10.1056/NEJMoa1607141
    [32] Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial[J]. Diabetes Care, 2019, 42: 1912-1920. doi:  10.2337/dc19-0415
    [33] He L, Zhang H. Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2021, 385: 2106-2107.
    [34] He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials[J]. JAMA Intern Med, 2022, 182: 513-519. doi:  10.1001/jamainternmed.2022.0338
    [35] Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study[J]. BMJ, 2018, 363: k4880.
    [36] Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss[J]. Am J Surg, 1995, 169: 91-96; discussion 96-97. doi:  10.1016/S0002-9610(99)80115-9
    [37] Shiffman ML, Kaplan GD, Brinkman-Kaplan V, et al. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program[J]. Ann Intern Med, 1995, 122: 899-905. doi:  10.7326/0003-4819-122-12-199506150-00002
    [38] He L, Wang J, Ping F, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials[J]. BMJ, 2022, 377: e068882.
  • 加载中
计量
  • 文章访问数:  57
  • HTML全文浏览量:  64
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-07-14
  • 录用日期:  2022-08-29
  • 网络出版日期:  2022-09-27
  • 刊出日期:  2022-11-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!